Primary resistance to nivolumab plus ipilimumab therapy in patients with metastatic renal cell carcinoma.
Kazuyuki NumakuraYuya SekineShingo HatakeyamaYumina MutoRyuta SobuMizuki KobayashiHajime SasagawaSoki KashimaRyohei YamamtoTaketoshi NaraHideo AkashiRyuji TabataSatoshi SatoMitsuru SaitoShintaro NaritaChikara OhyamaTomonori HabuchiPublished in: Cancer medicine (2023)
PRD was strongly correlated with worse survival rates. LNM was independently associated with PRD in patients with mRCC receiving NIVO+IPI as first-line therapy and might indicate that a candidate will not benefit from NIVO+IPI.